CCND1 and ovarian cancer: To begin with, GSK-3 (Glycogen synthase kinase 3) can participate in the proliferation of female ovarian cancer cells by accelerating the expression level of cyclin D1, which is expected to be an explorable and therapeutic direction for OC [35].